Recent Event Highlights: BEST RELATIVE PERFORMANCE IN THE HEALTH CARE SERVICES INDUSTRY DETECTED IN ... - Zacks.com, Quest Diagnostics' $200 Million Mystery - Wall Street Journal (blog), Earnings Scorecard: Quest Diagnostics - Zacks.com, Quest Diagnostics CE Marks Simplexa™ Tests for Epstein Barr and BK Viruses ... - PR Newswire (press release), Glaxo First-Quarter Net Rises on Gain From Quest Stake Sale; Revenue Falls - Bloomberg, Quest Diagnostics (DGX) Down 1.9% Despite EVA Dimensions, LLC Upgrade - Market Intelligence Center, and 227 more...
Created by dipity on May 14, 2009
Last updated: 05/02/11 at 12:12 PM
Quest Diagnostics has no followers yet. Be the first one to follow.
BEST RELATIVE PERFORMANCE IN THE HEALTH CARE SERVICES INDUSTRY DETECTED IN ...Zacks.comQuest Diagnostics (NYSE:DGX) ranks first with a gain of 0.73%; Laboratory Corp of America Holdings (NYSE:LH) ranks second with a gain of 0.72%; and Mednax (NYSE:MD) ranks third with a gain of 0.68%. Catalyst Health Solutions (NASDAQ:CHSI) follows with ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFqIIcT0esnPWm1JYb3-7LFDqrpJQ&url=http://www.zacks.com/research/get_news.php?id%3D122l4276
Quest Diagnostics' $200 Million MysteryWall Street Journal (blog)Word of a crucial scientific study helped medical-services company Quest Diagnostics negotiate a nearly $200 million discount in its deal to acquire Celera Corp. Yet one puzzle remains unsolved. Just how did Quest learn about the ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGYUiEHehDu0jV-T8enMybuqDUCTw&url=http://blogs.wsj.com/deals/2011/05/02/quest-diagnostics-200-million-mystery/
Earnings Scorecard: Quest DiagnosticsZacks.comThe announcement of Quest Diagnostics' (DGX - Analyst Report) first quarter of fiscal 2011 results as on April 20, 2011, has triggered analysts to revise estimates downwards. Quest Diagnostics reported an adjusted EPS of $1.00 during the first quarter ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEFalDlMrUBA8dWeIp3F5aO98-Vlw&url=http://www.zacks.com/stock/news/52362/Earnings%2BScorecard%253A%2BQuest%2BDiagnostics
Quest Diagnostics CE Marks Simplexa™ Tests for Epstein Barr and BK Viruses ...PR Newswire (press release)"Infection with EBV or BK virus poses a major health threat to certain immunocompromised patients, such as those who have recently undergone organ transplantation," said Jay M. Lieberman, MD, medical director for Quest Diagnostics and Focus Diagnostics ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNE3feAG19IglmPAJ4GwcHyGEZMb5g&url=http://www.prnewswire.com/news-releases/quest-diagnostics-ce-marks-simplexa-tests-for-epstein-barr-and-bk-viruses-for-sale-in-europe-120861744.html
RTT NewsGlaxo First-Quarter Net Rises on Gain From Quest Stake Sale; Revenue FallsBloombergGlaxoSmithKline Plc (GSK), the UK's biggest drugmaker, reported a 14 percent increase in first- quarter profit, helped by a gain from the sale of its stake in Quest Diagnostics Inc. Net income rose to ...Glaxo's Profit Rises, but Sales Fall 11%Wall Street JournalDisposals cushion GSK profit as drug sales fallReutersMixed 1Q from Glaxo as Weak Sales Weigh on GrowthHemscottNews & Observer -Express.co.ukall 73 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHFgPt6e6x8v2vOgZtE1lBeG981Jg&url=http://www.bloomberg.com/news/2011-04-27/glaxosmithkline-first-quarter-earnings-per-share-surpass-analyst-estimates.html
Quest Diagnostics (DGX) Down 1.9% Despite EVA Dimensions, LLC UpgradeMarket Intelligence CenterQuest Diagnostics (DGX) was upgraded today by analysts at EVA Dimensions, LLC and the stock is now at $56.78, down $1.08 (-1.87%) on volume of 1281932 shares traded. EVA Dimensions, LLC upgraded the stock to Overweight from Hold. ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHVmQGEANs3Q5bhne0w7UPokVB8ng&url=http://www.marketintelligencecenter.com/newsbites/1268087
Quest Diagnostics, Laredo TX local.lmtonline.com Because it's more than just a blood test, High quality testing and services, Skilled, Blood testing, professional staff, Quality, Convenient location on Calton Rd.,Diagnostic insights, Growing international presence, Specimen collection options, innovation and accountability, Patient comes first, Integrity
Quest Diagnostics (NYSE:DGX) reported Q1 EPS of $1.00, just off the consensus estimate for $1.01 per share. Revenues for the quarter grew 1% year-over-year to $1.82 billion, just above the consensus estimate for $1.81 billion. For the full year 2011 the company sees Revenue growth of approximately 2%, and adjusted EPS between $4.25 and $4.45, vs. the consensus Wall Street estimate of $4.44 per share. Surya N. Mohapatra, Ph.D., Chairman and Chief Executive Officer, said: "This was an important quarter for Quest Diagnostics. We completed our acquisition of Athena Diagnostics, and established the leading position in the neurology diagnostics market. We also announced our proposed acquisition of Celera to further strengthen our leadership position in cardiovascular testing as well as molecular diagnostics products and discovery. These transactions position us well for the future.
The Star-Ledger - NJ.comQuest Diagnostics net profit fallsReutersNEW YORK, April 20 (Reuters) - Quest Diagnostics Inc (DGX.N), the No. 1 lab-testing company, posted a 13 percent decline in quarterly net profit as severe storms pressured testing volumes. First-quarter net income fell to $140.8 million, ...Weather, job cuts hit Quest Diagnostics' 1Q profitForbesQuest Diagnostics Sees 10% Slide in 1Q Profit Amid Bad Weather, CostsFox BusinessQuest Diagnostics 1Q Profit Falls 13% On ChargesNASDAQSacramento Bee -Zacks.com -Seeking Alphaall 49 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEHcY-QEPApM_RrMkRl8iiPggCSVw&url=http://www.reuters.com/article/2011/04/20/questdiagnostics-idUSN2026849320110420
TRADING HIGHER ON HEAVY VOLUME ARE SHARES OF QUEST DIAGNOSTICS ON 1.1X ABOVE ...Zacks.comApr 19, 2011 (SmarTrend(R) News Watch via COMTEX) -- Shares of Quest Diagnostics (NYSE:DGX) are trading up 1.3% to $59.04 today on above average volume. Approximately 1.5 million shares have traded hands today vs. average 30-day volume of 1.4 million ...Options Brief: Quest Diagnostics Incorporated (DGX)Benzingaall 5 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGo5JtNDYRDjzDkG8llqZRsSCIfig&url=http://www.zacks.com/research/get_news.php?id%3D109l6773
Breakup Fee Lowered for Celera-Quest DealWall Street JournalCelera Corp. agreed to amend the terms of its sale to Quest Diagnostics Inc. to settle lawsuits filed in Delaware and California. Quest Diagnostics agreed in March to acquire Celera, a genetic-diagnostics test developer, ...Celera Tentatively Settles Suit Over $8-a-Share Quest BidBusinessWeekQuest Diagnostics Extends Tender Offer To Acquire Celera - Quick FactsRTT NewsQuest Diagnostics Extends Tender Offer for all Outstanding Shares of Celera ...PR Newswire (press release)Automated Trader -Centre Daily Timesall 44 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFa2BgkoH3Lqm4dhU_RJe8cIqp6TA&url=http://online.wsj.com/article/SB10001424052748703916004576270811293458344.html
www.Care360.com - Introducing the Care360 EHR Road Test tour. Quest Diagnostics is hitting the road to empower small physician practices across the country to embrace the power of electronic health record (EHR) solutions. Featuring a state-of-the-art mobile experience, the Care360 EHR Road Test tour will put physicians in the driver's seat, coupling insights on EHR benefits and available federal incentives with a "hands-on" introduction to our industry-leading Care360 EHR solution.
Quest Diagnostics to Release First Quarter 2011 Financial ResultsPR Newswire (press release)MADISON, NJ, April 12, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report first-quarter 2011 results on Wednesday, April 20, ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFr4g32-qS20pSH6ppcFp4DqDX8qg&url=http://www.prnewswire.com/news-releases/quest-diagnostics-to-release-first-quarter-2011-financial-results-119722909.html
Vermillion (VRML) announced today that it has signed an agreement with Quest Diagnostics (DGX) to make OVA1, an in vitro software-based diagnostics, available in India. OVA1, which the companies hope to launch in the second quarter of 2011, is the first protein-based multi-variate index assay (IVDMIA), a new class of state of the art software-based diagnostics, cleared by the FDA. Combined with ultrasound, OVA1's high sensitivity for ovarian malignancy can be used to detect the likelihood of malignancy in women with an ovarian mass for whom surgery is planned. Shares of Vermillion are down 2.11% to $4.65 while shares of Quest Diagnostics are up 0.47% to $57.71.
The majority of people with diabetes and/or high blood pressure -- the two leading causes of chronic kidney disease (CKD) -- are not receiving recommended tests to identify this disease early, when medical treatment can slow or halt disease progression.
I'm Christina Collins with CRWE Newswire --- Today's company highlight is Quest Diagnostics Incorporated trading with the symbol DGX --- Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions--- The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff--- Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care ---Quest Diagnostics has entered recently into a definitive merger agreement under which the company will acquire Celera Corporation --- Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries---Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management---For Quest Diagnostics, this is an important transaction which will further strengthen its leadership position in molecular diagnostics discovery and development and drive sustainable revenue growth--- Quest Diagnostics will gain immediate access to an impressive range of proprietary tests and products, and a strong pipeline of biomarkers ...
Celera (CRA) opens sharply higher after it says it will be bought by Quest Diagnostics (DGX) for $8 per share, representing a transaction value of approximately $344 million. DGX says it expects the acquisition to be dilutive to its GAAP EPS by an immaterial amount in 2011, before anticipated charges related to the transaction. The acquisition is not expected to have a material impact on DGX's 2012 EPS. Assuming a close of the transaction at the end of April, DGX says it expects CRA to add just over 1% to its 2011 revenue growth. Shares of CRA were last at a 52-week high of $8.15.
The Healthcare Heroes awards program will honor individuals and organizations that are making a significant impact on the quality of healthcare. Quest Diagnostics provides our customers with a comprehensive menu of routine and specialty laboratory tests and services. With the consolidated capabilities of our regional laboratories, expanding international presence and the additional esoteric capabilities of Nichols Institute, we are able to offer unequaled convenience in utilizing one laboratory for all diagnostic and prognostic clinical testing needs.
Nearly one third of pregnant women are not being screened by a simple laboratory test for gestational diabetes mellitus (gestational diabetes), according to a study of more than 900000 American women published online in Obstetrics and Gynecology. The study, conducted by scientists at Quest Diagnostics, suggests that a large number of women are not being screened according to medical guidelines and may unknowingly put themselves and their babies at risk for complications from gestational diabetes. Read the Press Release: ir.questdiagnostics.com Visit Quest Diagnostics: www.QuestDiagnostics.com
Quest Diagnostics (NYSE:DGX) reported Q4 EPS of $0.97, topping consensus estimates of $0.91 per share. Revenues for the quarter fell 1.3% year-over-year to $1.82 billion, marginally ahead of consensus estimates of $1.80 billion. The company expects 2011 EPS of $4.10 to $4.30, vs. consensus estimates of $4.29 per share. The board of directors approved a $750 million share repurchase authorization, bringing total available to $1 billion. Surya N. Mohapatra, Ph.D., Chairman and Chief Executive Officer said, "We generated strong cash flow in the quarter, and were encouraged by the continued improvement in our volume trends and the stability in revenue per requisition, We have taken actions to strengthen our sales organization, expand our pipeline of new tests and services, and improve our operating efficiency, which position us for revenue and EPS growth."
www.quest.com
How to tutorial on making an appointment with Quest Diagnostics
Boston Hep-B Screening Event With Free Testing From Quest Diagnostics. Chinese Consolidated Benevolent Association - 90 Tyler Street, Chinatown. Sunday, December 5th 9am - 12pm
"Morgan Stanley analysts said they now model calendar year 2010 EPS of $3.99 for Quest Diagnostics (NYSE:DGX), down from $4.01, compared to updated management guidance of $3.95 to $4.00 and consensus of $3.99 per share. Analysts Ricky Goldwasser, Donald Hooker, Andrew Schenker and Claire Diesen said, ""We assume 4Q10 volumes down 0.5% YoY, as the slowdown in physician visits and insourcing continue to hold back results. We model 4Q pricing down 2.2% YoY, reflecting the difficult 4Q09 comps associated with managed care contract repricing. For CY11, we now model EPS of $4.34(from $4.32), compared to consensus of $4.33. We forecast flat volume growth in the year as utilization anniversaries and pricing down 0.23%."" The bank maintained its underweight rating on the stock, with a $58 price target."
Associated Clinical Laboratories Erie PA www.localedge.com erie pa clinical tests, medical testing, Heathcare professionals, clinical blood work, clinical testing, erie pa blood work, clinical laboratory,Blood testing, blood work, quest diagnostics,
"Quest Diagnostics Inc. (NYSE:DGX) reported Q3 EPS of $1.13, ahead of consensus estimates of $1.01 per share. Revenues fell 1.7% year-over-year to $1.90 billion, ahead of consensus estimates of $1.87 billion. The company sees full-year 2010 EPS of $3.95 to $4.00, vs. consensus estimates of $3.99 per share. The company offered this statement, ""We grew earnings in the third quarter despite continued softness in physician office visits. While revenue was down, we are confident in the future and are making progress executing our plans to accelerate profitable growth - by promoting new gene-based and esoteric tests, enhancing sales effectiveness and improving operational efficiency, Furthermore, we are committed to using our substantial cash flow to generate value for our shareholders through both acquisitions and share repurchases. So far this year, we have returned $750 million to our shareholders through share repurchases, and now have flexibility to make $250 million of additional repurchases in the fourth quarter."" Quest Diagnostics has a potential upside of 8.5% based on a current price of $51.57 and an average consensus analyst price target of $55.93."
India Pakistan Independence day at Quest Diagnostics, Teterboro, NJ
Shares of Quest Diagnostics Inc. (NYSE:DGX) dipped 5.6% earlier Wednesday, following the company's Q2 earnings report, which showed revenue of $1.87 billion, off 1.4%, and a 3.3% drop in shares outstanding. Street estimates expected revenue of $1.93 billion, or $1.06 per share. The diagnostics testing and information services company slashed its 2010 outlook from $4.00-$4.20 per share, to $3.90-$4.00 per share, with a 1% decline in revenue.SmarTrend alerted subscribers to take profits in Quest Diagnostics on May 04, 2010 at $56.01; since then the stock fell 15.6%. We are now watching for any positive developments that could result in a new uptrend signal. Quest Diagnostics is currently below its 50-day moving average (MA) of $51.91 and below its 200-day MA of $56.25. In the last five trading sessions, the 50-day MA has fallen 1.1% while the 200-day MA has slid 0.1%. Shares of the company continue to trade down 5.39% Wednesday afternoon at $47.26.
Meet the CEO who led Quest Diagnostics to global leadership
Watch Bill Germanakos, Winner of Season Four of "The Biggest Loser", and Quest Diagnostics Wellness Ambassador as he takes to the scale to win the weight loss competition.
Sight & Sound Events,'CEO of FUN, Jodi Harris and her 'Party Patrol' of DJ David & 2 of the hottest hip-hop dancers in Vegas rocked the Loews Lake Las Vegas Resort Monday, April 19th for executives from Quest Diagnostics. These are two of the meeting planners, responible for selecting Sight & Sound from the other entertainment companies they interviewed in Las Vegas. As you can see they're very happy! You'll be too!
From our laboratory to yours. This video shows how to set up your 3M Integrated Cycler instrument and use the innovative software and Universal Disc to perform your laboratory testing. Focus Diagnostics and 3M have partnered to bring the 3M Integrated Cycler to the molecular marketplace. Within a square foot of bench space, the 3M Integrated Cycler can process up to 96 patient samples per run in less than 80 minutes. Class 1 laser product DANGER--Laser radiation when open and interlock defeated. AVOID EYE OR SKIN EXPOSURE TO DIRECT OR SCATTERED RADIATION
Debbies Kids, The Biggest Winners, Inspirational Journey, Brandon's Lightening Bolts, Quest Diagnostics and the Blues Brothers walking at the 7th Annual MDA Metro NY/NJ/CT Stride & Ride!
On October 12, 2009 Quest Diagnostics opened its new facility in Dublin, Ireland. Through a contract with the Irish National Cancer Screening Service (NCSS), Quest Diagnostics provides quality-assured screening services intended to improve medical outcomes and reduce anxiety wait time for women ages 25 to 60 who participate in Ireland's first nationwide cytology-screening program, CervicalCheck.
Quest Diagnostics on Harbor Blvd., Fullerton, California
The Focus Diagnostics and 3M partnership brings the well-known quality, content and expertise of each organization to the molecular marketplace. The 3M Integrated Cycler is an innovation in real-time PCR instrumentation, offering scalability unlike any instrument currently available. Within a square foot of bench space the 3M Integrated Cycler can process up to 96 patient samples per run in less than 80 minutes. The intuitive software is LIS compatible, generates run reports, and allows users to build cycling parameters. The bar-code scanner decreases transcription error and facilitates sample loading. Class 1 laser product DANGER--Laser radiation when open and interlock defeated. AVOID EYE OR SKIN EXPOSURE TO DIRECT OR SCATTERED RADIATION
While conventional tests look for cancer cells in bone marrow or, in certain cases, peripheral blood, LEUMETA cancer assays track genetic components of leukemia and lymphoma tumors, including messenger RNA, DNA and protein in blood plasma the liquid portion of the blood. Studies performed at Quest Diagnostics and The University of Texas MD Anderson Cancer Center and presented at the American Society of Hematology (ASH) meeting in December 2005 showed that information about tumor load and blood cancer markers of leukemia and lymphoma tumors is contained in blood plasma. Sample collection for these LEUMETA assays does not require the painful extraction of bone marrow cells with a large-bore needle through the hipbone. Using these tests, doctors can get a more frequent indication of a patients disease status and decide whether to alter their treatment, explained Francis Giles, MD, Professor of Medicine and Chief of Developmental Therapeutics within the Department of Leukemia at the MD Anderson Cancer Center, Houston. In an era of increasing focus on targeted therapies, the ability to sequentially obtain so much data from blood plasma specimens is a major help in optimally using the available therapies, and in assessing the efficacy of novel agents. To obtain this data without the need for bone marrow tissue is a major advance. Developed by a team of researchers at Quest Diagnostics using licensed technology discovered by one of the researchers while previously at MD Anderson ...
Watch the video "Beat the Disease to the Market" to learn Quest Diagnostics' approach to developing diagnostics for infectious diseases, including the 2009 H1N1 flu virus.
Practice Fusion addresses the critical needs of today's healthcare sector by providing a revolutionary application and delivery model for physicians and patients at no cost. Practice Fusion's award-winning, free, web-based applications require no on-site software, hardware and integration, eliminating the burden of supporting traditional enterprise software products. As a result, Practice Fusion dramatically reduces costs and complexities, enabling medical practitioners to deliver the highest level of care possible to their patients. practicefusion.com learn.practicefusion.com http practicefusion.com
Mere Dholna dance by Anjali Suman at Quest Diagnostics, Teterboro, NJ on India Pakistan Independence day celebration on August 19, 2009.
Excerpt
2009-08-14 17:56:01 -
diagnostic testing market. The leadership position allows the company to leverage its large asset base for more favorable outcomes during contract negotiations with payers. Quest mitigates the potential for physicians
Source Info
PR-Inside.com
http://www.pr-inside.com/fitch-assigns-initial-bbb-idr-to-r1437704.htm
Excerpt
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.
Source Info
SocialPicks
http://feedproxy.google.com/~r/SocialpicksRecentPicks/~3/AAcErjbYC0M/256385
In the land of logistics for a Fortune 500 company, something evil lurks amongst the halls. Quest Diagnostics yields itself to 12% of the nation's medical testing, should exorcism be its next endeavor?
Excerpt
Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its
Source Info
RedOrbit
http://www.redorbit.com/news/health/1736674/quest_diagnostics_declares_quarterly_cash_dividend/index.html?source=r_health
Excerpt
Wisconsin has received $44,954.80 as its share of a $12.4 million multistate settlement by Quest Diagnostics Inc. over allegations of faulty medical-testing kits, the state attorney general's office announced Tuesday.
Attorney General J.B. Van Hollen
Source Info
Business Journal of Milwaukee
http://feeds.bizjournals.com/~r/bizj_milwaukee/~3/_E81lmnfT1E/daily21.html
Excerpt
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.
Source Info
SocialPicks
http://feedproxy.google.com/~r/SocialpicksRecentPicks/~3/dWbhExXRSuY/255766
Update Sources